
Why the Five and One?
Health care doesn't fail women because we lack information. It fails because systems are slow to change, and they're rarely built around women's bodies, lives, or timelines. The Five & One exists to make those systems visible.
Every other week, we share five signals shaping women's health, plus one thing just for you.
This week
This week, the theme is spotting trouble sooner. A new Mayo Clinic study shows that not every BRCA2 gene change carries the same breast cancer risk. A large survey finds that nearly a third of women with autoimmune diseases wait four years or longer for a diagnosis, while nearly half of men are diagnosed within a year. Women are also more often told their symptoms are stress. The federal health department opened a funding call to update the guidelines for women's preventive care. A new report shows measles can reach pregnant women who have no proof of protection. And an early study finds a blood test picked up the earliest signs linked to ovarian cancer in more than 9 in 10 women who had them (92.3%), and correctly cleared 98.2% of healthy women. Plus, a +1 from our founder at the HLTH conference.
Free, forever. If you want more than the newsletter, there's an invitation waiting for you further down.
01. Not All BRCA2 Gene Changes Carry the Same Risk
Mayo Clinic researchers found that some BRCA2 gene changes carry a lower breast cancer risk than the well-known harmful ones. BRCA2 is a gene that helps stop tumors by repairing damaged DNA. Most people have heard that a harmful change in it raises breast cancer risk a lot. This study looked at 70 changes that only partly stop the gene from doing its job. It was published Nov 17 in Nature Communications, and Mayo worked with researchers from Ambry Genetics, a genetic testing company.
The Breakdown
The risk sits in the middle. Women who carry these partly working changes have an estimated lifetime breast cancer risk of 20% to 25%. One report puts the average woman's lifetime risk at 13%. The more common harmful BRCA2 changes carry a 50% to 70% risk.
Screening and surgery choices. Carriers may still benefit from regular mammograms and breast MRI, a more detailed scan. A clearer risk number could also matter for women thinking about surgery to lower their risk.
Clues for treatment. Some tumors linked to these changes may respond to a cancer drug called a PARP inhibitor. It blocks cancer cells from repairing their DNA. Testing the tumor may help decide if that drug fits.
A small share of cases, and more to find. The lead researcher, Dr. Fergus Couch, says a small share of breast cancers are likely caused by these changes. His team is still searching for similar changes in both BRCA1 and BRCA2.
The Breakthrough
Not every BRCA2 result means the same thing, and doctors are learning to tell the difference. Dr. Couch says that once all of these partly working changes are found, doctors can better match prevention, screening and treatment to a person's real risk. That is a future goal, not a change to today's guidelines. If you have had genetic testing, ask your genetic counselor or doctor whether your exact result is well understood and what screening fits it. Do not change your care without talking to your own doctor.
Source: KIMT
Also useful: Yahoo
02. Women Wait Years for an Autoimmune Diagnosis
A large survey found that women with autoimmune diseases wait longer for a diagnosis than men, and are more often told the cause is stress or a mental health problem. Autoimmune diseases happen when the body's defenses attack the body itself. A large survey finds that nearly a third of women with autoimmune diseases wait four years or longer for a diagnosis, while nearly half of men are diagnosed within a year. Women are also more often told their symptoms are stress.
The Breakdown
The wait is long. Nearly a third of the women surveyed waited four years or longer. Nearly half of the men were diagnosed within a year.
Many women wait more than a year. The article says 60.4% of women waited more than a year for a correct diagnosis.
Misdiagnosis runs along gender lines. About 34% of women were told their symptoms were psychosomatic (caused by stress or the mind), compared with 22% of men.
The gap is big. Women were almost 50% more likely to report a psychiatric misdiagnosis and nearly 75% more likely to report a psychosomatic one.
The Breakthrough
The article says women account for 70% to 80% of autoimmune cases worldwide. It points to older biases, thin research on women, and biased data as possible reasons for the gap. If you have symptoms that keep coming back, keep a simple log with dates and what you felt. Then ask your doctor, "What else could this be?" and whether a specialist visit makes sense.
Source: Euronews
03. A $1 Million Plan to Update Women's Preventive Care Rules
HHS opened a funding call for a group to update the guidelines for women's preventive care. The program is called the Women's Initiative for Screening and Health. HHS announced it Nov 6. It would fund one organization with up to $1 million in fiscal year 2027.
The Breakdown
What the group would do. It would bring together a panel of at least 10 experts, review the evidence using National Academies standards, and write information for communities with fewer resources.
Why the guidelines matter. A 2022 HHS report estimated about 58 million women had private insurance that covered preventive services without a copay.
Who can apply, and when. One organization will be chosen. Applications are due January 8, 2027.
It builds on existing work. HHS says the program builds on the guideline work supported by HRSA (the federal health resources agency) since 2016.
The Breakthrough
Who writes the guidelines helps decide which care is easy to get. This is a quiet move with real reach, because guidelines shape what insurers cover. Nothing changes for patients today, and the money is a ceiling, not a promise. Watch for who is chosen and how open the process is. In the meantime, you can read your own plan's list of covered preventive services, and ask your clinician which screenings are due for you.
Source: HHS
04. Measles Is Reaching Pregnant Women, Mostly the Unvaccinated
A new report from federal health researchers describes 112 pregnancies with measles in the U.S., almost all in women without measles shots. The report came from a joint project of NEJM Evidence and a University of Minnesota center. It covers January 2025 to September 28, 2026, from 16 states and local health departments. It is not a national total.
The Breakdown
Almost none had protection. 110 of the 112 women (98%) had no measles vaccine doses or an unknown vaccine history.
Illness was serious. 23% were admitted to the hospital for reasons unrelated to labor and birth, and 10% had pneumonia.
Babies were affected. 13 babies were born with measles. Of 21 pregnancies with outcomes within 14 days of the rash, 19 were live births and 2 were losses. Eight of the 19 babies were born early and 8 went to a newborn intensive care unit.
There is a treatment step. The report notes that CDC recommends an antibody treatment (immunoglobulin) for exposed pregnant women who have no proof of immunity.
The Breakthrough
This is a preventable risk, and the best time to act is before pregnancy. If you might become pregnant, ask your clinician to check that you have proof of measles protection, such as vaccine records or a blood test. If you are pregnant and think you were exposed, call your clinician right away and do not wait for symptoms. Decisions about vaccines and pregnancy are best made with your own doctor.
Source: University of Minnesota
05. A Blood Test May Spot Ovarian Cancer's Earliest Sign
A new blood test found early changes linked to ovarian cancer in most of the women who had them. Ovarian cancer is hard to catch early, and there is no routine screening test for it. Researchers tested a blood marker that picks up tiny early changes in the fallopian tubes. In the study, it found those changes in more than 9 in 10 women (92.3%) who had them.
The Breakdown
It looks for an early warning sign. Ovarian cancer can start as tiny changes in the lining of the fallopian tube, the tube that carries an egg toward the uterus. Women with these changes had higher blood levels of an RNA molecule called Tu-Stroma.
It cleared nearly all healthy women. The test correctly cleared 98.2% of women who did not have these changes.
Risk level changes how useful a result is. In women with genetic risk factors for ovarian cancer, about 72% of positive results would be right. Negative results were right nearly 100% of the time.
It is early. This is a research finding, and the news report mentions no plans yet for a larger trial.
The Breakthrough
For a cancer with no routine screening, this is a step toward one. The researchers say it could someday help women at high risk decide about surgery to remove the tubes and ovaries, by showing whether early changes are already there. That is a long way off, and the test is not available to patients. For now, the useful move is to know your family history. If ovarian or breast cancer runs in your family, ask your doctor whether genetic counseling makes sense for you
Source: BDNews24
Not a Member Yet?
This newsletter is free, and it always will be. But it's only part of what 51& offers. Members get tools to find and afford the right care, discounts with women's health brands, events with the people building this field, and a voice in the advocacy work we do in Washington. When we speak to lawmakers, we speak for our members, not just ourselves. Join us at member.51and.com.
. . .
Your+1: Jodi was at HLTH this week
Our founder took the HLTH stage to ask two HHS leaders what is changing in women's health. On Monday at HLTH in Las Vegas, Jodi Neuhauser, founder and CEO of 51&, sat down with Dr. Dorothy Fink of the National Institute of Child Health and Human Development (NICHD) and Chris Klomp, Chief Counselor at HHS. Jodi named the mood in the room. Many people have not heard about the progress, and some are doubtful after funding cuts and rollbacks. So they asked the real questions.
Here is what stuck with her.
A new home for women's health research. The new executive order creates a Women's Health Division at NICHD. It can fund grants directly and oversee scientific review, which the existing Office of Research on Women's Health was never set up to do. Dr. Fink pointed to endometriosis, which still takes 7 to 10 years to diagnose.
Billing codes shape the picture. The head of CMS, the Medicare and Medicaid agency, is on the task force on purpose. Billing codes drive what shows up in health records. When fibroids are tagged as cancer care, a payer can look at its data and decide it barely spends on women's health. Fix the codes, fix the picture.
Prices. Jodi paid $432 for the fertility drug Menopur in Cape Town. The same drug runs $5,000 to $7,000 in the U.S. Most favored nation pricing is expected to bring common fertility drugs down 40% to 60%, with more women's health drugs to follow.
Proof that teamwork works. The Maternal Perinatal Improvement Collaborative, across more than 200 hospitals, showed a 41.5% drop in delivery-related deaths, compared with 5.9% at similar hospitals. Those lessons are now moving into fertility.
The takeaway is public-private partnership. Government can put the dollars and the codes in the right place. Industry's job is to show up on Capitol Hill for funding, surface the payment roadblocks, and close the data loop. If you are building in women's health and hitting a payment or innovation roadblock, reach out to 51& so Jodi can route it to the right people.
P.S. You made it to the bottom, which means you are now the person at brunch who can say, "Actually, not every BRCA2 change carries the same risk." We are proud of you. Please use this power gently, and then use it to nudge a friend to ask her doctor the follow-up question she has been saving since spring.